Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Four-week, Phase IIa, Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Switching Subjects From a Stable Dose of Recombinant Human Erythropoietin to GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease

NCT01587924 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01587924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01587924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Four-week, Phase IIa, Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Switching Subjects From a Stable Dose of Recombinant Human Erythropoietin to GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
May 23, 2012
Completion date
May 27, 2013
Enrollment
80 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

anaemia